A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Connect Biopharma Holdings LTD stock. As of the latest transaction made, Renaissance Technologies LLC holds 212,300 shares of CNTB stock, worth $267,498. This represents 0.0% of its overall portfolio holdings.

Number of Shares
212,300
Previous 239,900 11.5%
Holding current value
$267,498
Previous $417,000 22.78%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$1.28 - $2.2 $35,328 - $60,720
-27,600 Reduced 11.5%
212,300 $322,000
Q1 2024

May 13, 2024

SELL
$1.01 - $1.74 $58,681 - $101,094
-58,100 Reduced 19.5%
239,900 $417,000
Q4 2023

Feb 13, 2024

BUY
$0.7 - $2.06 $140,700 - $414,060
201,000 Added 207.22%
298,000 $352,000
Q3 2023

Nov 14, 2023

BUY
$0.65 - $1.18 $975 - $1,770
1,500 Added 1.57%
97,000 $79,000
Q2 2023

Aug 11, 2023

BUY
$1.01 - $1.25 $6,464 - $8,000
6,400 Added 7.18%
95,500 $108,000
Q1 2023

May 12, 2023

BUY
$0.82 - $1.32 $4,264 - $6,864
5,200 Added 6.2%
89,100 $89,000
Q4 2022

Feb 13, 2023

BUY
$0.64 - $1.31 $384 - $786
600 Added 0.72%
83,900 $73,000
Q3 2022

Nov 14, 2022

BUY
$0.8 - $1.65 $13,120 - $27,060
16,400 Added 24.51%
83,300 $107,000
Q2 2022

Aug 12, 2022

BUY
$0.56 - $3.25 $24,304 - $141,050
43,400 Added 184.68%
66,900 $58,000
Q1 2022

May 13, 2022

BUY
$2.46 - $5.92 $31,242 - $75,184
12,700 Added 117.59%
23,500 $71,000
Q4 2021

Feb 11, 2022

BUY
$4.26 - $23.33 $46,008 - $251,963
10,800 New
10,800 $56,000

Others Institutions Holding CNTB

About Connect Biopharma Holdings Ltd


  • Ticker CNTB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,015,800
  • Market Cap $69.3M
  • Description
  • Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for t...
More about CNTB
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.